Abstract
Recent studies describe a heterogeneous population of cells of the myeloid lineage, termed myeloid derived suppressor cells (MDSC), which are observed with increased prevalence in the peripheral blood and tumor microenvironment of cancer patients, including pancreatic cancer. Accumulation of MDSC in the peripheral circulation has been related to extent of disease, and correlates with stage. MDSC have primarily been implicated in promoting tumor growth by suppressing antitumor immunity. There is also compelling evidence MDSC are also involved in angiogenesis and metastatic spread. Two main subsets of MDSC have been identified in cancer patients: a monocytic subset, characterized by expression of CD14, and a granulocytic subset characterized by expression of CD15. Both subsets of MDSC actively suppress host immunity through a variety of mechanisms including production of reactive oxygen species and arginase. Just as in humans, accumulation of monocytic and granulocytic MDSC has been noted in the bone marrow, spleen, peripheral circulation, and tumors of tumor bearing mice. Successful targeting of MDSC in mice is associated with improved immune responses, delayed tumor growth, improved survival, and increased efficacy of vaccine therapy. By further elucidating mechanisms of MDSC recruitment and maintenance in the tumor environment, strategies could be developed to reverse immune tolerance to tumor. We discuss here what is currently known about MDSC as well as some potential strategies targeting MDSC in the context of our work on pancreatic cancer and recent literature. Due to the number of new reports on MDSC, the most pertinent ones have been selected.
Keywords: Myeloid-derived suppressor cells, pancreatic cancer, immune suppression, bone marrow, metastasis, Mesothelin, premetastatic niche, myelopoiesis, Zoledronic acid, indoleamine 2,3-dioxygenase, inducible nitric oxide synthase
Current Cancer Drug Targets
Title: Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer
Volume: 11 Issue: 6
Author(s): P. Goedegebuure, J. B. Mitchem, M. R. Porembka, M. C.B. Tan, B. A. Belt, A. Wang-Gillam, W. E. Gillanders, W. G. Hawkins and D. C. Linehan
Affiliation:
Keywords: Myeloid-derived suppressor cells, pancreatic cancer, immune suppression, bone marrow, metastasis, Mesothelin, premetastatic niche, myelopoiesis, Zoledronic acid, indoleamine 2,3-dioxygenase, inducible nitric oxide synthase
Abstract: Recent studies describe a heterogeneous population of cells of the myeloid lineage, termed myeloid derived suppressor cells (MDSC), which are observed with increased prevalence in the peripheral blood and tumor microenvironment of cancer patients, including pancreatic cancer. Accumulation of MDSC in the peripheral circulation has been related to extent of disease, and correlates with stage. MDSC have primarily been implicated in promoting tumor growth by suppressing antitumor immunity. There is also compelling evidence MDSC are also involved in angiogenesis and metastatic spread. Two main subsets of MDSC have been identified in cancer patients: a monocytic subset, characterized by expression of CD14, and a granulocytic subset characterized by expression of CD15. Both subsets of MDSC actively suppress host immunity through a variety of mechanisms including production of reactive oxygen species and arginase. Just as in humans, accumulation of monocytic and granulocytic MDSC has been noted in the bone marrow, spleen, peripheral circulation, and tumors of tumor bearing mice. Successful targeting of MDSC in mice is associated with improved immune responses, delayed tumor growth, improved survival, and increased efficacy of vaccine therapy. By further elucidating mechanisms of MDSC recruitment and maintenance in the tumor environment, strategies could be developed to reverse immune tolerance to tumor. We discuss here what is currently known about MDSC as well as some potential strategies targeting MDSC in the context of our work on pancreatic cancer and recent literature. Due to the number of new reports on MDSC, the most pertinent ones have been selected.
Export Options
About this article
Cite this article as:
Goedegebuure P., B. Mitchem J., R. Porembka M., C.B. Tan M., A. Belt B., Wang-Gillam A., E. Gillanders W., G. Hawkins W. and C. Linehan D., Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer, Current Cancer Drug Targets 2011; 11 (6) . https://dx.doi.org/10.2174/156800911796191024
DOI https://dx.doi.org/10.2174/156800911796191024 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Quantification of SPECT and PET for Drug Development
Current Radiopharmaceuticals Toward Inhibitors of Protein Tyrosine Phosphatases for Cancer Treatment
Current Enzyme Inhibition Policy and Adolescent Tobacco Use Prevention
Adolescent Psychiatry Biomimetic Mineralization of Tumor Targeted Ferromagnetic Iron Oxide Nanoparticles Used for Media of Magnetic Hyperthermia
Current Drug Delivery The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Current Cancer Drug Targets Signal Transduction Pathway Regulated by Genistein and its Therapeutic Use
Current Signal Transduction Therapy Emerging Role of Apelin as a Therapeutic Target in Cancer: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Interaction Partners of the PDZ Domain of Erbin
Protein & Peptide Letters Emerging Role of Cetuximab in the Treatment of Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry Post-Translational Modifications of Nuclear Co-repressor RIP140: A Therapeutic Target for Metabolic Diseases
Current Medicinal Chemistry Glycosylation of Tetraspanin Tspan-1 at Four Distinct Sites Promotes Its Transition Through the Endoplasmic Reticulum
Protein & Peptide Letters The Management of Membranous Glomerulopathy in Allogeneic Stem Cells Transplantation: Updated Literature
Cardiovascular & Hematological Agents in Medicinal Chemistry RUNX2 and Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Simulation of Microgravity for Studies in Gravitational Biology: Principles, Devices and Applications
Current Biotechnology Galvez-Markov Network Transferability Indices: Review of Classic Theory and New Model for Perturbations in Metabolic Reactions
Current Drug Metabolism Review of Chemoradiotherapy for High-Risk Prostate Cancer
Reviews on Recent Clinical Trials Pancreatic Cancer Therapy Review: From Classic Therapeutic Agents to Modern Nanotechnologies
Current Drug Metabolism Cystine Dimethyl Ester Induces Apoptosis Through Regulation of PKC-δ and PKC-ε in Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry The Role of Tumor Suppressor Dysregulation in Prostate Cancer Progression
Current Drug Targets